1,1'-氧基二(2-丁醇) | 74262-24-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1,1'-氧基二(2-丁醇)
• 中文别名: 吡啶,2-肼基-6-甲氧基-
• 英文名称: 5-oxanonane-3,7-diol
• 英文别名: 1,1'-oxybisbutan-2-ol；2-hydroxybutyl ether；dipropylene glycol；1-(2-hydroxybutoxy)butan-2-ol
• CAS: 74262-24-1
• 化学式: C₈H₁₈O₃
• 分子量: 162.229
• InChiKey: VKWZWOKLRQWMPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2'-thiodiethanoyl chloride 、 1,1'-氧基二(2-丁醇) 以 苯 为溶剂， 以6%的产率得到8,12-diethyl-1,7,10-trioxa-4-thiacyclododecane-2,6-dione
  参考文献：
  名称：

  Synthesis of diethyl, di-n-octyl, and mono- and dicyclohexano macrocyclic polyether-diester ligands

  摘要：

  DOI：

  10.1021/jo01306a003
• 作为产物：
  描述：

  1,2-环氧丁烷 、 1,2-丁二醇 在 sodium 作用下， 反应 16.0h， 以60%的产率得到1,1'-氧基二(2-丁醇)
  参考文献：
  名称：

  Synthesis of diethyl, di-n-octyl, and mono- and dicyclohexano macrocyclic polyether-diester ligands

  摘要：

  DOI：

  10.1021/jo01306a003

文献信息

• COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES
  申请人：California Institute of Technology

  公开号：US20170049903A1

  公开（公告）日：2017-02-23

  The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:

  该发明提供了一种含有聚合物和治疗剂的颗粒复合物的组合物。该组合物还包含一种络合剂。聚合物与络合剂在宿主-客体或客体-宿主相互作用中相互作用，形成包含复合物。该发明的治疗组合物可用于传递治疗剂并治疗各种疾病。颗粒复合物的聚合物和络合剂均可用于向治疗组合物引入功能。该发明还涉及一种制备组合物的方法。该方法将治疗剂、具有宿主或客体功能的聚合物以及具有客体或宿主功能的络合剂结合在一起，形成治疗组合物。络合剂与聚合物形成包含复合物。该发明还涉及一种传递治疗剂的方法。根据该方法，在确实需要治疗的已知需要治疗的哺乳动物（例如人或动物）体内给予该发明的治疗组合物的治疗有效量。还披露了具有以下结构的化合物：
• LINEAR CYCLODEXTRIN COPOLYMERS
  申请人：California Institute of Technology

  公开号：US20180030207A1

  公开（公告）日：2018-02-01

  Linear cyclodextrin copolymers and linear oxidized cyclodextrin copolymers containing an unoxidized and/or an oxidized cyclodextrin moiety integrated into the polymer backbone are described. Methods of preparing such copolymers are also described. The linear cyclodextrin copolymer and linear oxidized cyclodextrin copolymer of the invention may be used as a delivery vehicle of various therapeutic agents.

  本发明涉及线性环糊精共聚物和线性氧化环糊精共聚物，其中包含未氧化和/或氧化的环糊精基团集成到聚合物骨架中。本发明还描述了制备这种共聚物的方法。本发明的线性环糊精共聚物和线性氧化环糊精共聚物可用作各种治疗剂的输送载体。
• Compositions containing inclusion complexes
  申请人：California Institute of Technology and Insert Therapeutics, Inc

  公开号：US20030008818A1

  公开（公告）日：2003-01-09

  The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula: 1

  本发明提供了一种含有聚合物和治疗剂的颗粒复合物的组合物。该组合物还包含一种络合剂。聚合物与络合剂通过主-客体或客-主体相互作用形成包含物复合物。本发明的治疗组合物可用于输送治疗剂并治疗各种疾病。颗粒复合物的聚合物和络合剂均可用于向治疗组合物引入功能。本发明还涉及一种制备组合物的方法。该方法将治疗剂、具有主或客体功能的聚合物和具有客体或主体功能的络合剂结合以形成治疗组合物。络合剂与聚合物形成包含物复合物。本发明还涉及一种输送治疗剂的方法。根据该方法，将本发明的治疗组合物的治疗有效量用于需要治疗的哺乳动物（例如人或动物）。还公开了具有式1的化合物：
• Complexing agents for compositions containing inclusion complexes
  申请人：California Institute of Technology and Insert Therapeutics, Inc

  公开号：US20030017972A1

  公开（公告）日：2003-01-23

  The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula: 1

  本发明提供了一种包含聚合物和治疗剂的颗粒复合物的组合物。该组合物还包含一个络合剂。聚合物与络合剂通过主客或客主相互作用形成包含复合物。本发明的治疗组合物可用于输送治疗剂并治疗各种疾病。颗粒复合物的聚合物和络合剂均可用于向治疗组合物引入功能。本发明还涉及一种制备组合物的方法。该方法将治疗剂、具有主或客功能的聚合物和具有客或主功能的络合剂结合以形成治疗组合物。络合剂与聚合物形成包含复合物。本发明还涉及一种输送治疗剂的方法。根据该方法，将本发明的治疗组合物的治疗有效量注入需要治疗的哺乳动物（例如人或动物）。还公开了具有以下公式的化合物：1
• Concentrated, stable, translucent or clear, fabric softening compositions including chelants
  申请人：Wahl Hoffman Errol

  公开号：US20050202998A1

  公开（公告）日：2005-09-15

  Clear or translucent fabric softening compositions having a biodegradable fabric softening active and an added chelating agent are disclosed. The biodegradable fabric softening active preferably has the formula: wherein each R substituent is hydrogen or a short chain C 1 -C 6 , preferably C 1 -C 3 alkyl or hydroxyalkyl group, e.g., methyl (most preferred), ethyl, propyl, hydroxyethyl, and the like, benzyl, or mixtures thereof; each m is 2 or 3; each n is from 1 to about 4, preferably 2; each Y is —O—(O)C—, —(R)N—(O)C—, —C(O)—N(R)—, or —C(O)—O—, preferably —O—(O)C—; the sum of carbons in each R 1 , plus one when Y is —O—(O)C— or —(R)N—(O)—, is C 6 -C 22 , preferably C 12-22 , more preferably C 14 -C 20 , but no more than one R 1 or YR 1 sum being less than about 12 and then the other R 1 or YR 1 sum is at least about 16, with each R 1 being a long chain C 5 -C 21 (or C 6 -C 22 ), preferably C 9 -C 19 (or C 9 -C 20 ), most preferably C 11 -C 17 (or C 12 -C 18 ), straight, branched, unsaturated or polyunsatruated alkyl, the average Iodine Value of the parent fatty acid of the R 1 being from about 20 to about 140. The chelating agent is preferably diaminetriaminepentaacetic acid. The compositions display excellant clarity with a percentage haze in the transmission mode of a Hunter Color analysis of less than 90%, preferably less than 50%.

  本文揭示了具有可生物降解织物柔软活性剂和添加螯合剂的透明或半透明织物柔软组合物。可生物降解织物柔软活性剂优选具有以下公式： 其中，每个R取代基是氢或短链C1-C6，优选是C1-C3烷基或羟基烷基，例如，甲基（最优选），乙基，丙基，羟乙基等，苯甲基或其混合物；每个m为2或3；每个n为1至约4，优选为2；每个Y为—O—（O）C—，—（R）N—（O）C—，—C（O）—N（R）—或—C（O）—O—，优选为—O—（O）C—；当Y为—O—（O）C—或—（R）N—（O）—时，每个R1中碳的总数加一为C6-C22，优选为C12-22，更优选为C14-C20，但不超过一个R1或YR1总和小于约12，然后另一个R1或YR1总和至少约为16，每个R1为长链C5-C21（或C6-C22），优选为C9-C19（或C9-C20），最优选为C11-C17（或C12-C18），直链、支链、不饱和或多不饱和烷基，R1的父脂肪酸的平均碘值约为20至约140。螯合剂优选为二氨基三乙酸五钠盐。该组合物在Hunter Color分析的透射模式下具有出色的清晰度，其百分之雾度小于90％，优选小于50％。